Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Multiple myeloma

M V Seiden1, K C Anderson

  • 1Dana Farber Cancer Institute, Boston, Massachusetts.

Current Opinion in Oncology
|January 1, 1994
PubMed
Summary
This summary is machine-generated.

Multiple myeloma, a cancer of plasma cells, leads to bone marrow accumulation and severe health issues. Current treatments offer only temporary relief, with disease recurrence being common and resistant to further therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A high-throughput platform for biophysical antibody developability assessment to enable AI/ML model training.

mAbs·2025
Same author

Report of consensus panel 7 from the 11th international workshop on Waldenström macroglobulinemia on priorities for novel clinical trials.

Seminars in hematology·2023
Same author

Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set.

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA.

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

Correction: Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond.

Leukemia·2019
Same author

Correction: Pomalidomide, bortezomib, and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma.

Leukemia·2018
Same journal

Artificial intelligence-augmented robotic surgery in gynecologic oncology: intraoperative assistance and analytics.

Current opinion in oncology·2026
Same journal

Artificial intelligence in cervical cancer screening and triage: a role-stratified systematic review and bivariate meta-analysis.

Current opinion in oncology·2026
Same journal

Deep learning assisting the surgical management of gynecologic cancers.

Current opinion in oncology·2026
Same journal

Pain management in pancreatic cancer: time to change our strategy!

Current opinion in oncology·2026
Same journal

Systemic radionuclide treatments in gastro-entero-pancreatic neuroendocrine tumours.

Current opinion in oncology·2026
Same journal

Lifestyle medicine for cancer survivorship.

Current opinion in oncology·2026
See all related articles

Area of Science:

  • Hematology
  • Oncology

Background:

  • Multiple myeloma is characterized by clonal plasma cell proliferation in bone marrow.
  • Disease progression causes immunosuppression, bone loss, anemia, and renal decline.
  • Current treatments like chemotherapy and radiotherapy provide only transient symptom relief.

Purpose of the Study:

  • To summarize the challenges in multiple myeloma management.
  • To highlight the limitations of existing therapeutic approaches.

Main Methods:

  • Literature review of multiple myeloma progression and treatment outcomes.
  • Analysis of disease-associated morbidities and treatment refractoriness.

Main Results:

  • Multiple myeloma mortality stems from progressive plasma cell accumulation.

Related Experiment Videos

  • Significant morbidity includes immunosuppression, bone turnover, anemia, and renal deterioration.
  • Recurrent disease, often refractory to therapy, is a common outcome.

    • Conclusions:

    • Existing treatments for multiple myeloma offer limited long-term efficacy.
    • The refractory nature of recurrent multiple myeloma necessitates novel therapeutic strategies.